← Medical · Causes of death · how systems treat it
Cancer · Master rank #18 · ~1.7% of deaths (Top 20 avg)
Short comparison of all 20 systems on one page. Click a country for the full treatment / prevention / lifestyle page.
High visit frequency, low unit prices, specialist access without US-style referral walls. Hep B/C control is the big lever in Asia. Cancer pathway via Statutory insurance, fee schedule.
High ambulatory volume; global budgets constrain growth. Hep B/C control is the big lever in Asia. Hep B vaccination success story; NHI covers antivirals
Public clusters for most serious care; private ISP for those who pay up. Hep B/C control is the big lever in Asia. Cancer pathway via S+3Ms (subsidy + MediSave + MediShield + MediFund).
Very high utilization; hospital-heavy; aggressive screening culture. Hep B/C control is the big lever in Asia. Cancer pathway via NHI single payer + private hospitals.
GP gatekeeping, NICE pathways, waiting-list rationing for elective care. Hep B/C control is the big lever in Asia. Cancer pathway via NHS tax-funded.
Strong primary care; Mediterranean public-health framing. Hep B/C control is the big lever in Asia. Cancer pathway via SNS tax-funded.
Fund-integrated care; strong tech/trauma capacity. Hep B/C control is the big lever in Asia. Cancer pathway via Mandatory health funds.
GP gatekeeping; north/south performance gaps. Hep B/C control is the big lever in Asia. Cancer pathway via SSN tax-funded.
Insurer-organized pathways; low uninsured rate. Hep B/C control is the big lever in Asia. Cancer pathway via Mandatory private insurance, regulated.
Primary-care centered; strong public health infrastructure. Hep B/C control is the big lever in Asia. Cancer pathway via Decentralized tax-funded.
Wealthy Nordic model; GP lists + municipal prevention. Hep B/C control is the big lever in Asia. Cancer pathway via Tax-funded national system.
Ambulatory specialist access; strong pharma/device availability. Hep B/C control is the big lever in Asia. Cancer pathway via Statutory health insurance.
High spend, high access, canton variation. Hep B/C control is the big lever in Asia. Cancer pathway via Mandatory private insurance.
Municipal prevention + regional hospitals. Hep B/C control is the big lever in Asia. Cancer pathway via Tax-funded.
Single-payer core with wait times; limited private parallel. Hep B/C control is the big lever in Asia. Cancer pathway via Single payer (provincial).
Ambulatory specialists + hospital sector; dense capacity. Hep B/C control is the big lever in Asia. Cancer pathway via Statutory sickness funds.
Public primary care + occupational health overlay. Hep B/C control is the big lever in Asia. Cancer pathway via Tax-funded / reforming.
Strong primary care gatekeeping with private hospital overflow. Hep B/C control is the big lever in Asia. Cancer pathway via Universal Medicare + private optional.
Pharmac constrains drug spend; public hospitals for major care. Hep B/C control is the big lever in Asia. Cancer pathway via Tax-funded + private optional.
High-tech acute care; prior auth; huge price variation by payer. Hep B/C control is the big lever in Asia. Cancer pathway via Medicare/Medicaid + commercial.